The　widespread　and　escalating　emergence　of　multidrug　resistance　is　now　recognized　as　one　of　the　most　severe　global　threats　to　human　health.　To　address　the　urgent　issue　of　drug-resistant　bacteria　and　the　limitation　of　effective　clinical　treatments,　antimicrobial　peptides　(AMPs)　have　been　developed　as　promising　substituents　of　conventional　antibiotics.　In　this　study,　rational　design　strategies　were　employed　to　acquire　seven　cationic　and　α-helical　engineered　peptides　based　on　the　original　template　of　Abaecin.　After　investigation,　we　found　that　AC7　(LLRRWKKLFKKIIRWPRPLPNPGH)　demonstrated　potent　and　broad-spectrum　antimicrobial　activity.　Additionally,　it　demonstrated　low　cytotoxicity　and　hemolysis　while　maintaining　good　stability.　Notably,　AC7　displays　the　antibacterial　mechanism　with　superior　abilities　in　cell　membrane　disruption　and　potential　DNA　binding　in　vitro,　as　well　as　effectively　disrupting　biofilms.　Moreover,　the　murine　skin　wound　model　infected　with　drug-resistant　Pseudomonas　aeruginosa　was　employed　to　evaluate　the　anti-infective　efficacy　and　therapeutic　potential　of　AC7.　It　was　observed　that　AC7　displays　a　remarkable　capacity　to　inhibit　wound　colonization,　reduce　levels　of　inflammatory　cytokines　(TNF-α)　and　inflammatory　cells　(white　blood　cells　(WBC),　monocytes　(MONO),　lymphocytes　(LYMPH),　neutrophils　(GRAN)),　promote　the　levels　of　IL-10　and　VEGF,　and　enhance　wound　healing.　Overall,　these　findings　demonstrate　the　potential　of　AC7　as　a　viable　alternative　to　traditional　antibiotics.　©　2023　American　Chemical　Society.